Investors Hopeful for Blockbusters From BioSante and Sunesis
May 26 2011 - 8:16AM
Marketwired
Recent studies have shown that the chances of FDA approval for
early stage drugs is dropping significantly. Although it remains an
exciting time in the biotech sector with several potential
blockbusters working their way through the regulatory process, now,
more than ever, many analysts are urging investors to use caution.
The Bedford Report examines the outlook for companies in the
Biotechnology Industry and provides research reports on BioSante
Pharmaceuticals, Inc. (NASDAQ: BPAX) and Sunesis Pharmaceuticals,
Inc. (NASDAQ: SNSS). Access to the full company reports can be
found at:
www.bedfordreport.com/2011-05-BPAX
www.bedfordreport.com/2011-05-SNSS
A study released by BIO and BioMedTracker claims that the
success rate in bringing new medicines to market in the past six
years is only about half of what it had been previously. The study
claims, however that biotech drugs are twice as likely to gain
approval, compared to more traditional chemical drugs.
The importance of maintaining a steady pipeline of drugs to
market is having varied effects on the biotechnology industry.
Larger firms are leaning on acquisitions to quickly expand their
product lines while smaller ones are opting for increased spending
on research and development. This creates two potential avenues of
profit for speculative biotech investors: a greater chance of a
blockbuster drug or being acquired by a larger firm eager to boost
its pipeline.
The Bedford Report releases regular market updates on the
Healthcare Sector so investors can stay ahead of the crowd and make
the best investment decisions to maximize their returns. Take a few
minutes to register with us free at www.bedfordreport.com and get
exclusive access to our numerous analyst reports and industry
newsletters.
BioSante is a pharmaceutical company focused on developing
products for female sexual health and oncology. In the most recent
quarter the company posted a wider loss on higher development costs
for its drug candidate "LibiGel." LibiGel is in late-stage clinical
trials and is intended to treat sexual dysfunction in women.
Sunesis Pharmaceuticals' most advanced drug candidate is
Vosaroxin, which is being studied as a treatment for acute myeloid
leukemia that has recurred or not responded to previous treatment.
The Food and Drug Administration awarded the drug "fast-track"
status earlier this year.
The Bedford Report provides Analyst Research focused on equities
that offer growth opportunities, value, and strong potential
return. We strive to provide the most up-to-date market activities.
We constantly create research reports and newsletters for our
members. The Bedford Report has not been compensated by any of the
above-mentioned publicly traded companies. The Bedford Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.bedfordreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: The Bedford Report Email Contact
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Sep 2023 to Sep 2024